Incidence and Screening of Retinopathy of Prematurity in Africa: A Systematic Review
NC06-NC10
Correspondence
Elizabeth Ndunge Mutua,
PO. Box 10315-00100 GPO, Nairobi, Kenya.
E-mail: elizabeth.mutua@strathmore.edu
Introduction: Retinopathy of Prematurity (ROP) significantly contributes to the statistics of blindness among babies born prematurely. Population-based studies of the disease in Africa is scanty with many African countries lacking screening guidelines.
Aim: To review the current statistics of ROP in Africa and present a summary of the incidence as well as the disease screening criteria within Africa.
Materials and Methods: An in-depth literature search was done on various databases following the guidelines provided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist for systematic review protocols. Some keywords guiding the search were “ROP,” “Retinopathy,” and “screening.” The International Prospective Register of Systematic Reviews (PROSPERO) registration (522296) was done, and databases were screened from inception up to December 2023 via African Journals Online (AJOL), Science Direct, Embase, Web of Science, Cumulated Index to Nursing and Allied Health Literature (CINAHL), PubMed, Ovid, and Medline. The inclusion criteria were English language studies about disease screening published from inception up to December 2023. Studies that did not include the number of babies screened or ROP screening criteria used, case studies, and duplicated studies were excluded. The Anatomical Quality Assessment tool (AQUA) was applied to confirm any bias and for reporting study results.
Results: A total of 15 articles were included, with sample sizes ranging from 33 to 424 participants. Two countries (Kenya and South Africa) have national screening guidelines, while for the rest of the countries in Africa, ROP is screened as per on the agreement of the ophthalmologists at each hospital.
Conclusion: The present review highlights the fact that ROP is the leading cause of blindness globally, yet there is little research being done on the statistics and screening of the disease. Many countries in Africa do not have national screening guidelines for the disease, which is a great challenge.